Da Eun Lee

Da Eun Lee

Auto-generated profile, based on publicly available information

Da Eun Lee

College of Pharmacy, Seoul National University, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
DLDa Eun Lee
Da Eun Lee
GLGeunho Lim
Geunho Lim
MKMinoh Ko
Minoh Ko
MKMari Kim
Mari Kim
JCJi Sun Chun
Ji Sun Chun
JOJung Mi Oh
Jung Mi Oh
Despite the immunomodulatory mechanism of immune checkpoint inhibitors (ICIs), systemic glucocorticoids are commonly used in advanced non–small cell lung cancer (NSCLC). Evidence regarding their effects on ICI outcomes is inconsistent, in part due to confounding by indication and immortal time bias. We conducted a multicenter target trial emulation to assess the association of glucocorticoid timing and dose with survival outcomes while addressing these biases. Patients with advanced NSCLC who initiated ICI therapy between 2015 and 2021 at four Korean tertiary hospitals were included. The primary endpoint was 2‐year overall survival (OS), with disease progression as a secondary endpoint. To minimize biases, outcomes were compared between concomitant glucocorticoid users and non‐users using time‐dependent propensity score matching. Among 1,815 eligible patients, 1,128 were matched. Hazard ratios (HRs) from the four institutions were pooled using a random‐effects meta‐analysis. Concomitant glucocorticoid use was associated with an increased risk of mortality (pooled aHR 1.36; 95% CI, 1.06–1.75). Early exposure within 90 days of ICI initiation was associated with poorer OS (aHR 1.49; 95% CI, 1.18–1.87), whereas later initiation showed no association. Dose‐stratified analyses showed that high‐dose exposure (> 1 mg/kg/day) was associated with reduced survival (aHR 1.61; 95% CI, 1.31–1.99), whereas low‐dose exposure was not associated with adverse outcomes. After accounting for confounding by indication and time‐related biases, concomitant systemic glucocorticoid use during ICI therapy was associated with less favorable survival outcomes. This association was more pronounced with early and high‐dose exposure, underscoring the clinical importance of glucocorticoid timing and dose.

18 August 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
DLDa Eun Lee
Da Eun Lee
JCJi Sun Chun
Ji Sun Chun
MKMari Kim
Mari Kim
IKIn-Wha Kim
In-Wha Kim
JOJung Mi Oh
Jung Mi Oh
Background: Accurate and up-to-date medicinal product information is essential for the safe and effective use of medicines. Electronic labeling (e-labeling) has emerged as a potential alternative to paper-based package inserts by enabling timely updates, improving accessibility, and supporting integration with digital health systems. However, regulatory approaches to pharmaceutical e-labeling remain fragmented across jurisdictions. Objective: This study examined how e-labeling policies have developed across International Coalition of Medicines Regulatory Authorities (ICMRA) member jurisdictions and explored the conditions associated with policies that position e-labeling as a replacement for paper-based product information. Methods: We conducted a cross-sectional comparative policy analysis of publicly available national regulatory documents on pharmaceutical e-labeling issued between January 1, 2012, and May 31, 2026. The analysis focused on how regulatory intent, legal authority, implementation mechanisms, and replacement pathways were articulated in official policy documents across jurisdictions. A main corpus of official jurisdictional policy documents was supplemented by a triangulation corpus of international stakeholder documents. Hybrid thematic analysis and content analysis were used to identify and compare policy themes across jurisdictions. A 4-level e-labeling regulatory maturity framework was developed using 3 indicators: implementation status, level of authority, and expansion toward advanced considerations. Fuzzy-set qualitative comparative analysis (fsQCA) was then conducted across 19 jurisdictions to identify configurational patterns associated with paper-label replacement. Results: A total of 81 policy documents from 20 jurisdictions were included in the main analysis, and 27 documents were included in the triangulation corpus. Nine themes were identified across 3 domains: e-labeling scope and implementation strategy, operational infrastructure, and advanced considerations. Most policies addressed target product information, medicine categories, transition approaches, interface mechanisms, and responsible entities. In contrast, structured digital formats, interoperability, and personalized information were less consistently addressed. The maturity assessment showed substantial variation across jurisdictions. Brazil and the Netherlands were classified at the highest maturity level, reflecting implementation with a legal basis and expansion toward advanced functions. The fsQCA identified 1 conservative sufficient configuration associated with paper-label replacement: digital infrastructure readiness, high e-labeling policy maturity, and explicit responsibility of the marketing authorization holder. Conclusions: Pharmaceutical e-labeling has moved beyond early policy discussion in many ICMRA member jurisdictions, but regulatory maturity remains uneven. While most jurisdictions enable electronic access to product information, relatively few have established the legal and operational foundations to replace paper labeling. Paper-label replacement was associated with mature regulatory frameworks and clear operational responsibility. By combining a cross-jurisdictional regulatory maturity framework with fsQCA, this study provides a novel comparative approach that extends beyond previous descriptive studies by identifying the conditions associated with paper-label replacement. The proposed framework may offer a structured approach to assessing regulatory readiness and prioritizing the efforts required for effective legal development and implementation.

1 April 2026 in JMIR Preprints
Verified
Preprint
Open access
DLDa Eun Lee
Da Eun Lee
JCJi Sun Chun
Ji Sun Chun
MKMari Kim
Mari Kim
IKIn-Wha Kim
In-Wha Kim
JOJung Mi Oh
Jung Mi Oh
BACKGROUND The dissemination of accurate, timely pharmaceutical product information is foundational to patient safety. Electronic labeling (e-labeling) has emerged as promising digital health approach that enables real-time updates, enhanced accessibility, and integration within digital health information ecosystems. Despite growing global adaptation, regulatory frameworks remain fragmented across jurisdictions, creating disparities in health information equity and posing challenges to patient safety in interconnected healthcare environments. OBJECTIVE This study aimed to systematically identify and compare national pharmaceutical e-labeling policies across major regulatory jurisdictions, assess regulatory readiness and policy maturity, characterize implementation strategies, identify critical governance gaps, and provide evidence-based recommendations for a harmonized global framework advancing digital health equity. METHODS We systematically searched and reviewed publicly available pharmaceutical e-labeling policy documents from International Coalition of Medicines Regulatory Authorities (ICMRA) member countries covering January 2012 to January 2024. Two independent reviewers screened and classified documents as “legal” (binding regulations) or “non-legal” (guidance) based on regulatory authority. A two-step analysis was employed: a hybrid thematic coding approach combining deductive coding based on three predetermined domains (scope and implementation, operational infrastructure, advanced digital health considerations) with inductive coding to generate nine themes from the data, followed by a comparative analysis of domain coverage, regulatory level, and regional distribution. Inter-rater reliability was assessed using Cohen's kappa coefficient. Policy maturity was classified across five levels based on regulatory authority and scope. RESULTS Among 22 ICMRA member countries, only 11 (50.0%) had accessible e-labeling policies, yielding 34 documents: 5 legal (14.7%), 29 non-legal (85.3%). All 11 countries addressed foundational implementation, scope and operational infrastructure, but only 9 (81.8%) covered advanced considerations including accessibility, interoperability, with electronic health records, or personalized information. Legally binding framework for basic implementation existed in merely 4 countries (36.4%) and only 2 countries (18.2%) had binding provisions for advanced features. The most sophisticated digital health capabilities, interoperability with clinical systems and personalized patient information, were addressed in only 3 countries (27.3%), through non-legal guidance. A sequential policy progression trend was observed, with nations prioritizing operational infrastructure before advancing to more complex considerations. Dual independent coding achieved excellent reliability (Cohen's kappa ≥0.95 for all domains). CONCLUSIONS Global pharmaceutical e-labeling policy development remains substantially fragmented with critical gaps in legal binding frameworks, technical standards, and patient-centered digital health integration. Only one-third of major regulatory markets possess legally binding implementation frameworks, while advanced interoperability and personalization capabilities remains largely unexplored. These findings highlight the urgent need for international harmonization through inter-agency collaboration, including adoption of binding minimum standards, machine-readable format mandates, and interoperability protocols aligned with global health informatics standards.